Sai Life Sciences Ltd
SAILIFE NSE
Sai Life Sciences Ltd
HealthcareNSE: SAILIFE BSE: 544306 Pharmaceuticals
Key Fundamentals
SmallcapPharmaceuticalsHealthcareMarket Cap
₹30,829 Cr
Volatility
High Risk
P/E Ratio
84.69
EBITDA
₹623 Cr
Return on Equity
7.99%
Debt to Equity
0.12
Book Value
₹116.99
52W High
₹1,475
52W Low
₹783.85
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sai Life Sciences Ltd insights
39 extracted metrics + investor summaries across FY19–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
1- Company has delivered good profit growth of 42.2% CAGR over last 5 years
Weaknesses
4- Stock is trading at 12.4 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.7% over last 3 years.
- Working capital days have increased from 51.8 days to 77.6 days
Growth Rate
Revenue Growth
26.64% ↗
Net Income Growth
122.10% ↗
Cash Flow Change
19.37% ↗
ROE
-5.89% ↗
ROCE
-1.49% ↗
EBITDA Margin (Avg.)
8.81% ↗
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 6d agoAI opinion · based on fundamentals
Risk high
Sai Life Sciences Ltd is a healthcare CDMO trading at a market cap of ₹30,596 Cr with a PE of 80x and P/B of 11.65x. The company has delivered strong profit growth of 42% CAGR over 5 years and 18% TTM sales growth, but carries an elevated valuation relative to its 15% last-year ROE and pays no dividend.
Bull Case 7
- Compounded profit growth of 42% CAGR over 5 years demonstrates strong earnings momentum in the CDMO space
- TTM sales growth of 18% indicates continued topline traction and demand visibility
- 3-year compounded sales CAGR of 22% shows consistent revenue scaling over a meaningful period
- 5-year compounded sales CAGR of 24% reflects a sustained long-term growth trajectory
- ROE improved to 15% in the last year from a 3-year average of 13%, indicating improving capital efficiency
- TTM profit growth of 51% suggests accelerating earnings relative to revenue growth of 18%, pointing to margin expansion
- Stock has delivered 65% returns over 1 year, reflecting strong market confidence in the business model
Bear Case 8
- PE ratio of 80x is significantly elevated versus healthcare sector averages, leaving limited margin of safety
- P/B ratio of 11.65x implies the stock trades at a steep premium to book value
- Zero dividend yield despite repeated profitability means shareholders receive no income return
- 3-year ROE of only 12.7% is modest for a company commanding an 80x PE multiple
- Working capital days have deteriorated from 51.8 days to 77.6 days, signaling potential cash conversion challenges
- 5-year average ROE of just 9% suggests historically weak return generation on equity capital
- 3-year compounded profit CAGR of 226% is driven by a low base, making future growth comparisons increasingly difficult
- At 80x earnings, even a minor miss on growth expectations could lead to significant multiple compression
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 3h ago Positives 1
- Q1FY27 profit up 22% YoY Aug 6
Standalone net profit rose 22% YoY to ₹713.39 million for Q1FY27, driven by higher revenue and lower finance costs.
Neutral 2
- Investor meetings in Singapore Aug 4
Sai Life Sciences scheduled analyst and investor meetings for August 13-14, 2026, in Singapore at the Avendus Spark INDX-Asia Edition 2026 event.
- Q1FY27 earnings call scheduled Jul 30
Company to host Q1FY27 earnings call on August 7, 2026, to discuss unaudited financial results for the quarter ended June 30, 2026.
TL;DR: Sai Life Sciences delivered solid Q1FY27 results with 22% profit growth supported by revenue expansion and lower finance costs. No headwinds are visible in recent news flow. Active investor engagement via Singapore meetings signals confidence in the growth narrative. The trend appears constructive heading into FY27 with clean financials and management accessibility.
Quarterly Results
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 384 | 439 | 280 | 396 | 440 | 580 | 496 | 537 | 556 | 602 | 554 |
| Expenses | 287 | 315 | 254 | 293 | 320 | 422 | 375 | 392 | 369 | 426 | 406 |
| Operating Profit | 96 | 125 | 26 | 102 | 120 | 158 | 121 | 146 | 188 | 177 | 148 |
| OPM % | 25% | 28% | 9% | 26% | 27% | 27% | 24% | 27% | 34% | 29% | 27% |
| Other Income | 11 | 3 | 8 | 10 | 9 | 10 | 10 | 15 | 0 | 16 | 4 |
| Interest | 23 | 21 | 21 | 21 | 23 | 11 | 12 | 9 | 10 | 8 | 8 |
| Depreciation | 31 | 31 | 31 | 36 | 34 | 37 | 38 | 40 | 44 | 45 | 46 |
| PBT | 53 | 76 | -18 | 55 | 72 | 119 | 81 | 112 | 134 | 139 | 98 |
| Tax % | 25% | 26% | -25% | 25% | 25% | 26% | 25% | 25% | 25% | 25% | 25% |
| Net Profit | 40 | 56 | -14 | 42 | 54 | 88 | 60 | 84 | 100 | 104 | 73 |
| EPS in Rs | — | — | — | — | 2.59 | 4.24 | 2.9 | 4 | 4.75 | 4.92 | 3.45 |
Profit & Loss
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 695 | 726 | 760 | 870 | 1,217 | 1,465 | 1,695 | 2,192 | 2,250 |
| Expenses | 520 | 558 | 593 | 743 | 1,048 | 1,178 | 1,285 | 1,561 | 1,592 |
| Operating Profit | 176 | 168 | 167 | 126 | 169 | 287 | 410 | 631 | 658 |
| OPM % | 25% | 23% | 22% | 15% | 14% | 20% | 24% | 29% | 29% |
| Other Income | 6 | 18 | 27 | 28 | 27 | 29 | 35 | 41 | 35 |
| Interest | 24 | 22 | 33 | 54 | 81 | 88 | 78 | 39 | 35 |
| Depreciation | 44 | 55 | 80 | 90 | 99 | 119 | 139 | 167 | 175 |
| PBT | 113 | 109 | 82 | 10 | 16 | 109 | 228 | 466 | 483 |
| Tax % | 35% | 30% | 25% | 36% | 39% | 24% | 25% | 25% | — |
| Net Profit | 73 | 76 | 61 | 6 | 10 | 83 | 170 | 349 | 362 |
| EPS in Rs | — | — | — | — | — | — | 8.16 | 16.48 | 17.12 |
| Div. Payout % | 0% | 0% | 0% | 1117% | 676% | 0% | 0% | 0% | — |
Balance Sheet
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 17 | 18 | 18 | 18 | 21 | 21 |
| Reserves | 703 | 778 | 845 | 861 | 870 | 957 | 2,108 | 2,463 |
| Borrowings | 249 | 304 | 637 | 752 | 933 | 928 | 352 | 288 |
| Other Liabilities | 247 | 312 | 318 | 527 | 358 | 359 | 665 | 854 |
| Total Liabilities | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 | 3,626 |
| Fixed Assets | 373 | 641 | 701 | 751 | 1,037 | 1,180 | 1,488 | 1,815 |
| CWIP | 116 | 91 | 246 | 410 | 151 | 107 | 124 | 270 |
| Investments | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 50 |
| Other Assets | 726 | 679 | 870 | 997 | 989 | 973 | 1,531 | 1,490 |
| Total Assets | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 | 3,626 |
Cash Flow
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating | 129 | 116 | -36 | 105 | 219 | 263 | 314 | 509 |
| Investing | -158 | -262 | -260 | -102 | -99 | -191 | -536 | -395 |
| Financing | 268 | -4 | 296 | 72 | -201 | -95 | 301 | -124 |
| Net Cash Flow | 239 | -150 | -1 | 75 | -80 | -24 | 79 | -10 |
| Free Cash Flow | -28 | -157 | -298 | -102 | 148 | 82 | -55 | -83 |
| CFO/OP | 90 | 81 | -13 | 90 | 132 | 96 | 82 | 87 |
Ratios
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 123 | 136 | 99 | 102 | 85 | 64 | 76 | 62 |
| Inventory Days | 86 | 79 | 127 | 179 | 121 | 72 | 93 | 97 |
| Days Payable | 207 | 258 | 230 | 279 | 180 | 113 | 253 | 182 |
| Cash Conversion Cycle | 1 | -43 | -4 | 2 | 25 | 22 | -83 | -24 |
| Working Capital Days | 55 | 24 | 62 | 42 | 36 | 12 | 66 | 78 |
| ROCE % | — | 13% | 9% | 3% | 6% | 11% | 14% | 20% |
Documents
1
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
15h - Earnings conference call invite for the quarter and year ended Financial Results ended on 31 March, 2026 15h - Earnings conference call invite for the quarter and year ended Financial Results ended on 31 March, 2026
2
Announcement under Regulation 30 (LODR)-Press Release / Media Release
10h - Sai Life Sciences' Bidar campus achieved 100% renewable electricity on 11 May 2026; 97% direct solar/wind, 35,110 tCO₂ saved. 10h - Sai Life Sciences' Bidar campus achieved 100% renewable electricity on 11 May 2026; 97% direct solar/wind, 35,110 tCO₂ saved.
3
Intimation Of An Order Dated 29Th April 2026 Issued By The Joint Commissioner Of Commercial Taxes (Appeals), Kalaburagi U/S 107 (11) Of The Central Goods And Services Tax Act, 2017 And The Karnataka Goods And Services Tax Act, 2017.
30 Apr - Karnataka GST appeals order demands ₹16.28 crore tax, ₹13.32 crore interest, ₹3.26 crore penalty. 30 Apr - Karnataka GST appeals order demands ₹16.28 crore tax, ₹13.32 crore interest, ₹3.26 crore penalty.
4
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
23 Apr - Allotment of 2,44,281 Equity Shares under ESOP Schemes of the Company. 23 Apr - Allotment of 2,44,281 Equity Shares under ESOP Schemes of the Company.
5
Intimation Of An Order Dated 29Th April 2026 Issued By The Joint Commissioner Of Commercial Taxes (Appeals), Kalaburagi U/S 107 (11) Of The Central Goods And Services Tax Act, 2017 And The Karnataka Goods And Services Tax Act, 2017.
30 Apr - Karnataka GST appeals order demands ₹16.28 crore tax, ₹13.32 crore interest, ₹3.26 crore penalty. 30 Apr - Karnataka GST appeals order demands ₹16.28 crore tax, ₹13.32 crore interest, ₹3.26 crore penalty.
Frequently Asked Questions about Sai Life Sciences Ltd
What does Sai Life Sciences Ltd do?
Incorporated in 1999, Sai Life Sciences
Ltd carries out contract research and manufacturing activities for customers
engaged in pharmaceutical and bio
technology industries[1]
Where is Sai Life Sciences Ltd (SAILIFE) listed?
Sai Life Sciences Ltd is listed on the Indian stock exchanges. It is listed on NSE: SAILIFE and BSE: 544306. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Sai Life Sciences Ltd belong to?
Sai Life Sciences Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Sai Life Sciences Ltd?
Sai Life Sciences Ltd has a market capitalisation of approximately ₹30828.87 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Sai Life Sciences Ltd?
The Price-to-Earnings (PE) ratio of Sai Life Sciences Ltd is 84.69. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Sai Life Sciences Ltd?
Over the past 52 weeks, Sai Life Sciences Ltd has traded between a low of ₹783.85 and a high of ₹1,475. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Sai Life Sciences Ltd?
Sai Life Sciences Ltd has a Return on Equity (ROE) of 7.99%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Sai Life Sciences Ltd on Tapetide?
On Tapetide, you can view Sai Life Sciences Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 1999, Sai Life Sciences Ltd carries out contract research and manufacturing activities for customers engaged in pharmaceutical and bio technology industries[1]